Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Review

Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society

Authors: Marcello Casaccia Bertoluci, Augusto Pimazoni-Netto, Antonio Carlos Pires, Antonio Eduardo Pesaro, Beatriz D Schaan, Bruno Caramelli, Carisi Anne Polanczyk, Carlos Vicente Serrano Júnior, Danielle M Gualandro, Domingos Augusto Malerbi, Emilio Moriguchi, Flavio Antonio de Oliveira Borelli, João Eduardo Nunes Salles, José Mariani Júnior, Luis Eduardo Rohde, Luis H Canani, Luiz Antonio Machado Cesar, Marcos Tambascia, Maria Tereza Zanella, Miguel Gus, Rafael Selbach Scheffel, Raul Dias dos Santos

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

There is a very well known correlation between diabetes and cardiovascular disease but many health care professionals are just concerned with glycemic control, ignoring the paramount importance of controlling other risk factors involved in the pathogenesis of serious cardiovascular diseases. This Position Statement from the Brazilian Diabetes Society was developed to promote increased awareness in relation to six crucial topics dealing with diabetes and cardiovascular disease: Glicemic Control, Cardiovascular Risk Stratification and Screening Coronary Artery Disease, Treatment of Dyslipidemia, Hypertension, Antiplatelet Therapy and Myocardial Revascularization. The issue of what would be the best algorithm for the use of statins in diabetic patients received a special attention and a new Brazilian algorithm was developed by our editorial committee. This document contains 38 recommendations which were classified by their levels of evidence (A, B, C and D). The Editorial Committee included 22 specialists with recognized expertise in diabetes and cardiology.
Appendix
Available only for authorised users
Literature
1.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329 (14): 977-986.CrossRef
2.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352 (9131): 837-853.CrossRef
3.
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352 (9131): 854-865.CrossRef
4.
Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358 (24): 2545-2559.CrossRefPubMed
5.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359 (15): 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed
6.
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009, 373 (9677): 1765-1772. 10.1016/S0140-6736(09)60697-8.CrossRefPubMed
7.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358 (24)): 2560-2572.PubMed
8.
The action to control cardiovascular risk in diabetes study group: Effects of intensive glucose lowering in type 2 diabetes. NEJM. 2008, 358: 2545-2559.PubMedCentralCrossRef
9.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators: Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009, 360 (2): 129-139. 10.1056/NEJMoa0808431.CrossRefPubMed
10.
Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M, Control Group: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009, 52 (11): 2288–98.11-CrossRef
11.
American Diabetes Association: Standards of medical care in diabetes--2014. Diabetes Care. 2014, 37 (Suppl 1): S14-S80.CrossRef
12.
Yudkin JS, Richter B, Gale EA: Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010, 53 (10): 2079-2085. 10.1007/s00125-010-1864-z.CrossRefPubMed
13.
Narayan KMV, Zhang P, Kanaya AM, Williams DE, Engelgau MM, Imperatore G, Ramachandran A: Diabetes: The Pandemic and Potential Solutions. Source: Disease Control Priorities in Developing Countries. Edited by: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P. 2006, Washington (DC): World Bank, Chapter 30, 2
14.
Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, Defronzo R, Cefalu WT: Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care. 2013, 36 (6): 1779-1788. 10.2337/dc13-0512.PubMedCentralCrossRefPubMed
15.
Malmberg K, DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997, 314 (7093): 1512-1515. 10.1136/bmj.314.7093.1512.PubMedCentralCrossRefPubMed
16.
Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenström A, DIGAMI 2 Investigators: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005, 26 (7): 650-661. 10.1093/eurheartj/ehi199.CrossRefPubMed
17.
Cheung NW, Wong VW, McLean M: The hyperglycemia: intensive insulin infusion in infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006, 29 (4): 765-770. 10.2337/diacare.29.04.06.dc05-1894.CrossRefPubMed
18.
Ledur P, Almeida L, Pellanda LC, Schaan BD: Clinical features and outcomes in patients with diabetes mellitus undergoing coronary artery bypass graft in a reference center in southern Brazil. Rev Assoc Med Bras. 2011, 57 (2): 200-204. 10.1590/S0104-42302011000200019.CrossRefPubMed
19.
Jones KW, Cain AS, Mitchell JH, Millar RC, Rimmasch HL, French TK, Abbate SL, Roberts CA, Stevenson SR, Marshall D, Lappé DL: Hyperglycemia predicts mortality after CABG: postoperative hyperglycemia predicts dramatic increases in mortality after coronary artery bypass graft surgery. J Diabetes Complications. 2008, 22 (6): 365-367. 10.1016/j.jdiacomp.2007.05.006.CrossRefPubMed
20.
Furnary AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999, 67 (2): 352-360. 10.1016/S0003-4975(99)00014-4. discussion 60–2CrossRefPubMed
21.
Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A: Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003, 125 (5): 1007-1021. 10.1067/mtc.2003.181.CrossRefPubMed
22.
van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med. 2001, 345 (19): 1359-1367. 10.1056/NEJMoa011300.CrossRefPubMed
23.
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ, NICE-SUGAR Study Investigators: Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009, 360 (13): 1283-1297.CrossRefPubMed
24.
Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S, Talmor D: Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009, 180 (8): 821-827. 10.1503/cmaj.090206. 12PubMedCentralCrossRefPubMed
25.
Lazar HL, McDonnell MM, Chipkin S, Fitzgerald C, Bliss C, Cabral H: Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients. Ann Surg. 2011, 254 (3): 458-463. 10.1097/SLA.0b013e31822c5d78. discussion 63–4CrossRefPubMed
26.
Stevens RJ1, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group: The UKPDS risk engine: a model for the risk of coronary heart disease in typeII Diabetes. (UKPDS 56). Clin Sci. 2001, 101: 671-679. 10.1042/CS20000335.CrossRefPubMed
27.
Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ: Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia. 2009, 52 (10): 2001-2014. 10.1007/s00125-009-1454-0. Epub 2009 Jul 24PubMedCentralCrossRefPubMed
28.
Kramer CK, Zinman B, Gross JL, Canani LH, Rodrigues TC, Azevedo MJ, Retnakaran R: Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: A systematic review and meta-analysis. BMJ. 2013, 346: f1654-10.1136/bmj.f1654.CrossRefPubMed
29.
Blaha MJ: Associations between C-reactive protein, coronary artery calcium and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort. Lancet. 2011, 378: 684-692. 10.1016/S0140-6736(11)60784-8.PubMedCentralCrossRefPubMed
30.
Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE, DIAD Investigators: Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009, 301 (15): 1547-1555. 10.1001/jama.2009.476.PubMedCentralCrossRefPubMed
31.
Bansal S, Wackers FJ, Inzucchi SE, Chyun DA, Davey JA, Staib LH, Young LH, DIAD Study Investigators: Five-year outcomes in high-risk participants in the detection of ischemia in asymptomatic diabetics (DIAD) study: a post hoc analysis. Diabetes Care. 2011, 34 (1): 204-209. 10.2337/dc10-1194.PubMedCentralCrossRefPubMed
32.
Cholesterol Treatment Trialist (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18.686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008, 371: 117-125.CrossRef
33.
Cholesterol Treatment Trialist (CTT) Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: a metanalysis of data from 170.000 participants in 26 randomised trials. Lancet. 2010, 376: 1670-1681.CrossRef
34.
Shepherd J, Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and Diabetes, The treating to New Targets (TNT) study. Diabetes Care. 2006, 29: 1220-1226. 10.2337/dc05-2465.CrossRefPubMed
35.
Goff DC, Lloyd-Jones DM, Bennett G, O'Donnell CJ, Coady S, Robinson J, D'Agostino RB, Schwartz JS, Gibbons R, Shero ST, Greenland P, Smith SC, Lackland DT, Sorlie P, Levy D, Stone NJ, Wilson PW: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, doi:10.1016/j.jacc.2013.11.005. [Epub ahead of print].
36.
Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC, Levy D, Watson K, Wilson PW: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, doi:10.1016/j.jacc.2013.11.002. [Epub ahead of print]
37.
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005, 353: 238-248. 10.1056/NEJMoa043545.CrossRefPubMed
38.
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F, AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Eng J Med. 2009, 360 (14): 1395-1407. 10.1056/NEJMoa0810177.CrossRef
39.
Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004, 110 (12): 1557-1563. 10.1161/01.CIR.0000143892.84582.60.CrossRefPubMed
40.
Investigators G-HF: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008, 372 (9645): 1231-1239. 10.1016/S0140-6736(08)61240-4.CrossRef
41.
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group: Rosuvastatin in older patients with Systolic Heart Failure. N Eng J Med. 2007, 357: 2248-2261. 10.1056/NEJMoa0706201.CrossRef
42.
Colhoun HM1, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvasatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004, 364 (9435): 685-696. 10.1016/S0140-6736(04)16895-5.CrossRefPubMed
43.
Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003, 361 (9374): 2005-2016.CrossRefPubMed
44.
Cholesterol Treatment Trialists (CTT) Collaborators: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012, 380: 581-590.CrossRef
45.
American Diabetes Association: Standards of medical care in diabetes 2014. Diabetes Care. 2014, 37 (1): S14-S79.CrossRef
46.
The Accord Study Group: Effects of combination lipid therapy in type 2 diabetes. NEJM. 2010, 362: 17-CrossRef
47.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002, 360 (9349): 1903-1913.CrossRefPubMed
48.
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research Group: Effect on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Eng J Med. 2001, 344 (1): 3-10. 10.1056/NEJM200101043440101.CrossRef
49.
Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P: Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011, 29: 1253-1269. 10.1097/HJH.0b013e3283469976.CrossRefPubMed
50.
51.
McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, Tonelli M, Leiter LA, Klarenbach SW, Manns BJ: Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Arch Intern Med. 2012, 172 (17): 1296-1303. 10.1001/archinternmed.2012.3147.CrossRefPubMed
52.
Blood Pressure Lowering Treatment Trialists’ Collaboration: Blood pressure lowering treatment effects of different blood pressure–lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005, 165: 1410-1419.CrossRef
53.
Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL: Comparative effectiveness of renin-angiotensin system blockers and other anti-hypertensive drugs in patients with diabetes: Systematic Review and Bayesian network meta-analysis. BMJ. 2013, 347: f6008-10.1136/bmj.f6008.PubMedCentralCrossRefPubMed
54.
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators: Benazepril plus Amlodipine or hydrochlorthiazide for hypertension in high-risk patients. N Engl J Med. 2008, 359 (23): 2417-2428. 10.1056/NEJMoa0806182.CrossRefPubMed
55.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345 (12): 861-10.1056/NEJMoa011161.CrossRefPubMed
56.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptorantagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345: 851-10.1056/NEJMoa011303.CrossRefPubMed
57.
Kunz R, Friedrich C, Wolbers M, Mann JFE: Meta-analysis: effect of monotherapy and combination therapy with Inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008, 148 (1): 30-48. 10.7326/0003-4819-148-1-200801010-00190.CrossRefPubMed
58.
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (The ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008, 372: 547-553. 10.1016/S0140-6736(08)61236-2.CrossRefPubMed
59.
Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A, Antithrombotic Trialists’ (ATT) Collaboration: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009, 373 (9678): 1849-1860.CrossRefPubMed
60.
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y: Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008, 300: 2134-2141. 10.1001/jama.2008.623.CrossRefPubMed
61.
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and anti-oxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008, 337: a1840-10.1136/bmj.a1840.PubMedCentralCrossRefPubMed
62.
Simpson SH, Gamble JM, Mereu L, Chambers T: Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med. 2011, 26 (11): 1336-1344. 10.1007/s11606-011-1757-y.PubMedCentralCrossRefPubMed
63.
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS: Aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association, a scientific atatement of the American Heart Assoiation, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010, 33 (6): 1395-1402. 10.2337/dc10-0555.PubMedCentralCrossRefPubMed
64.
De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, Nicolucci A: Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomized controlled trials. BMJ. 2009, 339: b4531-10.1136/bmj.b4531.PubMedCentralCrossRefPubMed
65.
Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J: Aspirin for primary prevention of cardiovascular events in patients with diabetes: a metanalysis. Diabetes Res Clin Pract. 2010, 87 (2): 211-218. 10.1016/j.diabres.2009.09.029.CrossRefPubMed
66.
He J: Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998, 280: 1930-1935. 10.1001/jama.280.22.1930.CrossRefPubMed
67.
Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, Lai CL, Wong J: Lansoprazole for the prevention of recurrences of ulcer complications for long-term low dose aspirin use. N Engl J Med. 2002, 346 (26): 2033-2038. 10.1056/NEJMoa012877.CrossRefPubMed
68.
CAPRIE Steering Committee: A randomised, blinded, trial f clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996, 348: 1329-1339.CrossRef
69.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001, 345: 494-502.CrossRef
70.
Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT (Clopidogrel and metoprolol in myocardial infarction trial) collaborative group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005, 366: 1607-1621.CrossRefPubMed
71.
Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E, CLARITY-TIMI 28 Investigators: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005, 352: 1179-1189. 10.1056/NEJMoa050522.CrossRefPubMed
72.
James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny FK, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L, For the PLATO study group: Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010, 32: 3006-3016.CrossRef
73.
Wiviott SD1, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with coronary syndromes. N Engl J Med. 2007, 357 (20): 2001-2015. 10.1056/NEJMoa0706482.CrossRefPubMed
74.
Hueb W, Gersh BJ, Costa F, Lopes N, Soares PR, Dutra P, Jatene F, Pereira AC, Góis AF, Oliveira SA, Ramires JA: Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg. 2007, 83 (1): 93-99. 10.1016/j.athoracsur.2006.08.050.CrossRefPubMed
75.
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Smith SC, Spertus JA, Williams SV, Anderson JL, American College of Cardiology Foundation/American Heart Association Task Force: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012, 126 (25): e354-e471. 10.1161/CIR.0b013e318277d6a0.CrossRefPubMed
76.
MEMBERS WC, Staff Pa, Foundation ACoC, Association ACoCFAH, Association AH: 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013, 127 (23): e663-e828.CrossRef
77.
O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, et al: 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013, 127 (4): e362-e425.CrossRefPubMed
78.
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007, 356 (15): 1503-1516. 10.1056/NEJMoa070829.CrossRefPubMed
79.
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996, 335 (4): 217-225.CrossRef
80.
Investigators B: The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007, 49 (15): 1600-1606.CrossRef
81.
Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ: Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009, 373 (9670): 1190-1197. 10.1016/S0140-6736(09)60552-3.CrossRefPubMed
82.
Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW: The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention. 2005, 1: 219-227.PubMed
83.
Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW: Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left-main coronary disease: 5-year follow-up of the randomized, clinical SYNTAX trial. Lancet. 2013, 381: 629-638. 10.1016/S0140-6736(13)60141-5.CrossRefPubMed
84.
Banning AP1, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW: Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010, 55 (11): 1067-1075. 10.1016/j.jacc.2009.09.057.CrossRefPubMed
85.
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V, FREEDOM Trial Investigators: Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012, 367 (25): 2375-2384. 10.1056/NEJMoa1211585.CrossRefPubMed
86.
Kappetein AP1, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ, SYNTAX Investigators: Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013, 43 (5): 1006-1013. 10.1093/ejcts/ezt017.CrossRefPubMed
87.
Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P: Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008, 337: a1331-10.1136/bmj.a1331.PubMedCentralCrossRefPubMed
88.
Onuma Y, Wykrzykowska JJ, Garg S, Vranckx P, Serruys PW, Investigators AIaI: 5-Year follow-up of coronary revascualarization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials. JACC Cardiovasc Interv. 2011, 4 (3): 317-323. 10.1016/j.jcin.2010.12.004.CrossRefPubMed
Metadata
Title
Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society
Authors
Marcello Casaccia Bertoluci
Augusto Pimazoni-Netto
Antonio Carlos Pires
Antonio Eduardo Pesaro
Beatriz D Schaan
Bruno Caramelli
Carisi Anne Polanczyk
Carlos Vicente Serrano Júnior
Danielle M Gualandro
Domingos Augusto Malerbi
Emilio Moriguchi
Flavio Antonio de Oliveira Borelli
João Eduardo Nunes Salles
José Mariani Júnior
Luis Eduardo Rohde
Luis H Canani
Luiz Antonio Machado Cesar
Marcos Tambascia
Maria Tereza Zanella
Miguel Gus
Rafael Selbach Scheffel
Raul Dias dos Santos
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-58

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue

Research

Association of lower limb muscle mass and energy expenditure with visceral fat mass in healthy men

Research

A descriptive study of health status and health related quality of life in selected outpatients with type 2 diabetes, pathological body mass index and cardiovascular risk in Spain

Research

Oxidized low density lipoprotein and total antioxidant capacity in type-2 diabetic and impaired glucose tolerance Saudi men

Research

Correlation between reduction of superior interventricular groove epicardial fat thickness and improvement of insulin resistance after weight loss in obese men

Research

Association between Brachial-Ankle pulse wave velocity and cardiac autonomic neuropathy in type 2 diabetes

Research

Metabolic profile response to administration of epigallocatechin-3-gallate in high-fat-fed mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits